FTC, Surmodics and GTCR
In the FTC’s first merger challenge of the new administration, the FTC voted 4-0 last week to challenge the proposed ...
Lake Street analyst Brooks O’Neil upgraded Surmodics (SRDX) to Buy from Hold with an unchanged price target of $43. The Federal Trade ...
The FTC has blocked GTCR's $627M acquisition of SRDX, citing anti-competitive concerns. Surmodics has responded to the challenge and plans to fight the decision in court. EDEN PRAIRIE, Minn., ...
On March 6, 2025, the Federal Trade Commission (FTC) filed a lawsuit in federal court challenging GTCR BC Holdings, LLC's (GTCR) proposed ...
Surmodics (NASDAQ:SRDX) edged lower by 0.7% amid a report that it's scheduled to meet with regulators this week to convince ...
Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.
The regulator says the proposed merger would give the combined company more than 50% of the market for a type of medical ...
6d
Fintel on MSNLake Street Upgrades Surmodics (SRDX)Fintel reports that on March 7, 2025, Lake Street upgraded their outlook for Surmodics (NasdaqGS:SRDX) from Hold to Buy.
On March 7, 2025, the FTC filed a complaint in federal court seeking to block GTCR BC Holdings, LLC, a Chicago private equity firm, from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results